Utilization Patterns of Stimulants in ADHD in the Medicaid Population: A Retrospective Analysis of Data from the Texas Medicaid Program

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages

  Lawson, Kenneth A ^a   Johnsrud, Michael ^b   Hodgkins, Paul ^c   Sasané, Rahul ^c   Crismon, M Lynn ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Avalere Health LLC   (United States)

^c SHIRE   (United States)

Author keywords

ADHD; Adherence; Medicaid; Persistence; Stimulant medication; Switching

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; SHORT ACTING DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES;

EID: 84859620753     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.021     Document Type: Article

References (42)

1. Harpin V.A. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005, (Suppl 1):i2-i7.
2. Guevara J., Lozano P., Wickizer T., et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:71-78.
3. Faraone S.V., Sergeant J., Gillberg C., Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2:104-113.
4. Polanczyk G., de Lima M.S., Horta B.L., et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948.
5. Skounti M., Philalithis A., Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 2007, 166:117-123.
6. Visser S.N., Bitsko R.H., Danielson M.L., Perou R. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR 2010, 59:1439-1443.
7. Biederman J., Wilens T., Spencer T. Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectr 2007, 12(Suppl 6):1-15.
8. Mannuzza S., Klein R.G., Bessler A., et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998, 155:493-498.
9. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163:716-723.
10. Simon V., Czobor P., Balint S., et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194:204-211.
11. Biederman J., Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248.
12. Searight H.R., Burke J.M., Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician 2000, 62. 2077-2072.
13. Spencer T.J. ADHD and comorbidity in childhood. J Clin Psychiatry 2006, (Suppl 8):27-31.
14. Wolraich M.L. Attention-deficit hyperactivity disorder. Semin Pediatr Neurol 2006, 13:279-285.
15. Biederman J., Faraone S.V., Spencer T.J., et al. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 2006, 67:524-540.
16. Hodgkins P., Montejano L., Sasané R., Huse D. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord 2011, 13:e1-e6.
17. Brown R.T., Amler R.W., Freeman W.S., et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005, 115:e749-e757.
18. Kessler R.C., Adler L.A., Barkley R., et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005, 57:1442-1451.
19. Marcus S.C., Wan G.J., Kemner J.E., Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005, 159:572-578.
20. Olfson M., Gameroff M.J., Marcus S.C., Jensen P.S. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003, 160:1071-1077.
21. Clinical Practice Guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:1033-1044. American Academy of Pediatrics Subcommittee on Attention-deficit/Hyperactivity disorder and Committee on Quality Improvement.
22. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005, 5:525-539.
23. Banaschewski T., Coghill D., Santosh P., et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006, 15:476-495.
24. Hammerness P., Surman C., Miller K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep 2008, 8:484-489.
25. Zuvekas S.H., Vitiello B., Norquist G.S. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006, 163:579-585.
26. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894-921.
27. Sallee F.R., McGough J., Wigal T., et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009, 48:155-165.
28. Christensen L., Sasane R., Hodgkins P., et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010, 26:977-989.
29. Biederman J., Newcorn J., Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991, 148:564-577.
30. Martin B.C., Wiley-Exley E.K., Richards S., et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009, 43:36-44.
31. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.
32. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
33. Chen L., McCombs J.S., Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value Health 2008, 11:34-43.
34. Barkley R.A., Fischer M., Smallish L., Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002, 111:279-289.
35. Swanson J.M., Lerner M., Wigal T., et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 2002, (Suppl 1):S73-S88.
36. Kemner J.E., Lage M.J. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry 2006, 5:5.
37. Ramos-Quiroga J.A., Bosch R., Castells X., et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008, 22:603-611.
38. Sanchez R.J., Crismon M.L., Barner J.C., et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005, 25:909-917.
39. Lage M., Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004, 14:575-581.
40. Olfson M., Marcus S.C., Zhang H.F., Wan G.J. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm 2007, 13:570-577.
41. Perwien A., Hall J., Swensen A., Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004, 10:122-129.
42. Winterstein A.G., Gerhard T., Shuster J., et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008, 42:24-31.